AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03412760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exome sequencing
Description: Expansive genetic test performed for affected fetus or neonate.
Study NCT00586625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepreve
Description: One drop, both eyes, twice a day
Study NCT00586625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop, both eyes, twice a day
Study NCT02831140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early exercises
Description: In postoperative phase:~Early exercises: within the first hour ;setting a half bed position, deep breathing and coughing . In the second hour, curbing vagal malaise and performing relaxation movements. In the third hour, walking about 20 to 30 minutes.
Study NCT02831140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Removing urinary probe and all catheters.
Description: In postoperative phase : Removing urinary probe and all catheters.
Study NCT02831140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early alimentation
Description: In postoperative phase :Early alimentation: in the first hour to the second hour .
Study NCT02831140 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: commun interventions
Description: * In preoperative phase: stopping smoking at least 2 weeks, hospitalization and balanced alimentation one day before the surgery.~* In peroperative phase : no use of benzodiazepines in the anesthesia , selective intubation , maintaining vital parameters as normal and using a mini invasive surgical approach ( video thoracoscopy , video assisted thoracoscopy , thoracotomy with preservation of the posterior muscles of the chest wall~  , preservation of Serratus anterior and the front part of Latissimus Dorsi ).~* In postoperative phase : Immediate extubation ( less than 30 minutes from the surgery end) , peridural or paravertebral or intercostal block analgesia , no use of abusive antibiotic , all analgesic drugs are permitted if there are no contraindications and physiotherapy from the 6th hour.
Study NCT01052571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar transforaminal epidural injections
Description: with an injection of local anesthetic or with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
Study NCT01752985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Study NCT00916123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-J591
Description: Two infusions of 177Lu-DOTA-J591 at 40 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
Study NCT01752985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-813160
Study NCT01752985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching with BMS-813160
Study NCT04539353 — intervention group
Intervention type: OTHER
Intervention: Heart Rate Variability
Description: Heart Rate Variability will be measured with a Polar device.
Study NCT04539353 — intervention group
Intervention type: OTHER
Intervention: Pain intensity
Description: Pain Intensity will be measured with a Numeric Rating Scale and Visual Analogue Scale
Study NCT00737243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2, 1-3 hour IV infusion Day 1
Study NCT00737243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6.0 IV Day 1
Study NCT00737243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV infusion Day 1
Study NCT01729819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin orally disintegrating tablets
Study NCT01729819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo orally disintegrating tablets
Study NCT01756417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: One 1,000 mg tablet of metformin taken orally (by mouth) on Day 1 and Day 8.
Study NCT01756417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: Four 25 mg tablets of canagliflozin (JNJ-28431754) taken orally on Days 4 through 8.
Study NCT04096144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuromuscular Blocking Agents
Description: Neuromuscular agents will be used to block muscle function for the safety and efficiency of the procedure. At the procedure's conclusion, neuromusclar agents such as Neostigmine or Sugammadex will be used to reverse the neuromuscular reversal.
Study NCT01654705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 40mg Delayed release tablets (Test Product)
Study NCT01654705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Protonix® Delayed Release 40 mg tablets (Reference product)
Study NCT02535624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PACKING
Description: By retroperitoneal access the space in front of the pelvic fracture is compressed with surgical towels, which stops effectively venous bleeding
Study NCT02535624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ANGIO
Description: Using en endovascular approach, bleeding arteries are identified and clotted using embolizing agents, or coils.
Study NCT01037530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: 5 mg/day for 2 weeks then 10 mg/day for 22 weeks
Study NCT03002844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TK Inhibitor
Description: EGFR-TKI (gefitinib 250mg per day)
Study NCT02798887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge preservation
Description: Ridge preservation comparing the clinical and histologic healing with or without a barrier membrane
Study NCT01217892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: 2.5 mg tablet, taken orally, twice daily
Study NCT01217892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: 5 mg tablet taken orally, twice daily
Study NCT01217892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: 10 mg tablet taken orally, once daily
Study NCT01217892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: >/= 1500 mg total daily dose, tablets taken orally, twice daily
Study NCT01217892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: >/= 1500 mg total daily dose, tablets taken orally, twice daily
Study NCT01217892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03359161 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: sc2Wear Furosemide Infusor
Description: Subcutaneous furosemide for the treatment of fluid overload
Study NCT04168125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tilapia skin
Description: Application tilapia skin as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
Study NCT03002844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKI
Description: EGFR-TKI (gefitinib 250mg per day)
Study NCT03002844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKI and Chemotherapy
Description: pemetrexed 500mg per kg q3w/gemcitabine 1000mg per kg q3w and carboplatin AUC=5 q3w
Study NCT01976754 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Septic patients are randomly received 1 of 6 doses( 0.2,0.3,0.4,0.5,0.6,0.7μg/kg/h) dexmedetomidine.
Study NCT03465007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: we will give IV Hydrocortisone 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD treatments.
Study NCT03465007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: we will give IV normal saline 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD
Study NCT03780816 — intervention group
Intervention type: OTHER
Intervention: Observation of provider-patient interactions and interviews
Description: Clinical interactions between cancer patients and providers will be observed and hand-written field notes recorded and later transcribed. Semi-structured interviews with providers, patients, caregivers, and other informants will take place following initial observation.
Study NCT05264467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin on colorectal anastomosis
Description: Platelet rich fibrin on colorectal anastomosis
Study NCT02039180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293 oral solution
Description: Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and solution as a single dose on Day 1, Day 8 or Day 15.
Study NCT02039180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293 tablet formulation A
Description: Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8, or Day 15.
Study NCT04622826 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immune plasma
Description: immune covid 19 plasma infusion
Study NCT02661035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 300 mg/day (for peds -150 mg/m\^2/day), day -6 and continue through day 0 or longer if clinically indicated
Study NCT02661035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 IV over 1 hour, day -6, -5, -4, -3 and -2
Study NCT02661035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg IV over 2 hours, day -6
Study NCT02661035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: Only for patients with an unrelated donor (URD) and NO multi-agent chemotherapy 3 months prior to transplant. ATG will be administered IV every 12 hours for 6 doses on days -6, -5, and -4 according to institutional guidelines. Methylprednisolone 1 mg/kg IV administered immediately prior to each dose of ATG (6 doses).
Study NCT02661035 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TBI
Description: All patients who have had previous radiation therapy or TBI will be seen by Radiation Oncology prior to entrance on the protocol for approval for additional 200 cGy of TBI. TBI may be delivered by local guidelines provided the effective dose is equivalent to what is recommended in the TBI Guidelines. The dose of TBI will be 200 cGy given in a single fraction on day -1.
Study NCT02661035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: All patients will receive tacrolimus therapy beginning on day -3. Initial dosing of tacrolimus will be 0.03 - 0.05 mg/kg/day IV; if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if ≥ 40 kg, twice daily or per current institutional guidelines.~An attempt will be made to maintain a trough level of 5-10 ng/mL and subsequent dose modifications will be provided by the pharmacist.~Once the patient can tolerate oral medications and has a reasonable oral intake, tacrolimus will be converted to an oral form based on the current IV dose providing normal renal and hepatic function and no major drug interactions.~The timing of the tacrolimus taper will be at the discretion of the treating physician, but in general:~* Taper begins at day +100 +/- 10 days, if the patient is stably engrafted and has no active GVHD.~* Taper to zero by reducing dose by approximately 10% a week (rounded to nearest pill size), with a goal to discontinue by month 6 post-HCT.
Study NCT02661035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~MMF will stop at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC) ≥ 0.5 x 109 /L\]). If no donor engraftment, MMF will continue as long as clinically indicated.
Study NCT02661035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cells
Description: On day 0, patients will receive an allogeneic transplant using PBSC which are CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
Study NCT02661035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Related or Unrelated Bone Marrow Cells
Description: On day 0, a target dose of 3 x 10\^8 nucleated cells/kg recipient weight will be collected. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
Study NCT04168125 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Wound Dressing
Description: Application surgical wound dressing as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
Study NCT04009070 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture Pres Needle: 0.22x1.5 mm needle
Description: Acupunctur group; Acupunctur preoperatively 24 hours before bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally from the tuberocyte tibia). The tape (Needle Press) will remain for 24 hours after surgery.
Study NCT00580437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dobutamine Stress Echocardiogram
Description: stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
Study NCT02039180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293 tablet formulation B
Description: Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8 or Day 15.
Study NCT01627067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg by mouth once daily.
Study NCT01627067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg by mouth once daily.
Study NCT01627067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg by mouth per day for three days. If there are no dose limiting toxicities, the dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily.
Study NCT05631015 — intervention group
Intervention type: OTHER
Intervention: AI recongnize disease and generate recommendations
Description: According the endoscopic reports and pathological reports, the decision support system recognise patients' disease types and grades, and generate guidelines based survilliance or treatment recommendations.
Study NCT00339183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab was administered by IV infusion on Day 1 of each 14-day cycle, just before administration of FOLFIRI chemotherapy.
Study NCT00339183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 racemate (or 200 mg/m\^2 I-leucovorin), 5-FU bolus 400 mg/m\^2, 5-FU infusion 2400 mg/m\^2.
Study NCT00339183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 racemate (or 200 mg/m\^2 I-leucovorin), 5-FU bolus 400 mg/m\^2, 5-FU infusion 2400 mg/m\^2.
Study NCT01226420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Given intravenously Days 1 and 4 of Week 1, then subcutaneously once weekly for Weeks 2-12
Study NCT03978819 — intervention group
Intervention type: DEVICE
Intervention: ANI
Description: ANI profiles during IPNS (bradycardia/asystole) or excessive analgesia.~During surgery continuous monitoring of ANI, HR and Remifentanil effect site concentration was done and recorded. Event markers were placed at the onset of bradycardia, asystole and the coincidence of ANI>80 + Remifentanil >6ng/mL). ANI values of 1 min before and 1 min after the event were used for analysis.
Study NCT03407924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AER)
Description: Aerobic exercise will be performed with a treadmill or stationary tandem bike 3 times per week. Each exercise session will take about 30 minutes plus 5 to 10 min of warm-up and cool-down. Participants will wear a safety harness.
Study NCT03407924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
Study NCT04048304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duration of standard antibiotic therapy
Description: antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.
Study NCT04048304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duration of standard antibiotic therapy
Description: antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.
Study NCT01145456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally
Study NCT01145456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT01145456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04345614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auxora
Description: Auxora will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Auxora will be administered intravenously (IV) over 4 hours.
Study NCT01145456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02135458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Study NCT02135458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Study NCT02135458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional care
Study NCT03771846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan, oxaliplatin , fluorouracil, and leucovorin
Description: administration of irinotecan, oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
Study NCT04345614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given at 1.25 mL/kg on Day 1 and then 1.0 mL/kg on Days 2 and 3. All doses of placebo will be administered intravenously over 4 hours.
Study NCT03771846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine and oxaliplatin
Description: administration of gemcitabine and oxaliplatin via vein
Study NCT02622659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xiaoer Jiebiao Oral Liquid
Description: 1\~2 years old: 5mL each time and twice a day~3\~5 years old: 5mL each time and three times a day~6\~14 years old: 10mL each time and twice a day
Study NCT03226171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-adjusted SK-1403
Description: SK-1403 is to be administered to patients for the whole treatment periods (52 weeks), with individual dose adjustment
Study NCT02323386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary Total Knee Arthroplasty (ATTUNE Knee System)
Description: The patient will undergo primary Total Knee ArthroplastY use ATTUNE Knee System. During surgery a navigation system will be used to record preoperative joint kinematics under different tests. During the test the 6 degrees of freedom (DOF) of the joint will be computed and shown to the surgeon; these are the femoral rotation and translation pattern against flexion ranges. Navigation system will be also used to monitor the implant positioning and possible surgical bias. Dynamic RSA will be used to analyze the in vivo kinematics of the prosthesis at 6 months follow-up.~The above mentioned motion tests will be performed 3 times. The first 2 will be executed to gain comfort with the experimental set-up with no X-ray exposure. During the last data is collected.